Abstract：
UNASSIGNED: Iron metabolism plays a significant role in the development of metabolic disorders in women with polycystic ovary syndrome (PCOS). Despite the importance of hepcidin, a key iron regulator, current research on serum hepcidin levels in PCOS patients shows conflicting results.
UNASSIGNED: PubMed, Embase, Web of Science, Cochrane Library and the China National Knowledge Infrastructure (CNKI) database were systematically searched from their inception to 9 September 2023. The search aimed to identify studies in English and Chinese that examined hepcidin levels in women with PCOS compared to healthy control subjects. Standardized mean differences (SMDs) with corresponding 95% confidence intervals (95% CIs) were calculated to evaluate the difference in serum hepcidin levels between women with and without PCOS.
UNASSIGNED: The meta-analysis included a total of 10 eligible studies, which encompassed 499 PCOS patients and 391 control subjects. The pooled analysis revealed a significant reduction in serum hepcidin levels among the PCOS patients compared to the healthy controls (SMD = -3.49, 95% CI: -4.68 to -2.30, p < .05). There was no statistically significant difference in serum hepcidin levels between PCOS patients with a body mass index (BMI) < 25 and those with a BMI ≥ 25 (p > .05).
UNASSIGNED: The serum hepcidin levels of women with PCOS were significantly lower than those of healthy controls, which suggests that serum hepcidin could be a potential biomarker for PCOS.
UNASSIGNED: PubMed, Embase, Web of Science, Cochrane Library and the China National Knowledge Infrastructure (CNKI) database were systematically searched from their inception to 9 September 2023. The search aimed to identify studies in English and Chinese that examined hepcidin levels in women with PCOS compared to healthy control subjects. Standardized mean differences (SMDs) with corresponding 95% confidence intervals (95% CIs) were calculated to evaluate the difference in serum hepcidin levels between women with and without PCOS.
UNASSIGNED: The meta-analysis included a total of 10 eligible studies, which encompassed 499 PCOS patients and 391 control subjects. The pooled analysis revealed a significant reduction in serum hepcidin levels among the PCOS patients compared to the healthy controls (SMD = -3.49, 95% CI: -4.68 to -2.30, p < .05). There was no statistically significant difference in serum hepcidin levels between PCOS patients with a body mass index (BMI) < 25 and those with a BMI ≥ 25 (p > .05).
UNASSIGNED: The serum hepcidin levels of women with PCOS were significantly lower than those of healthy controls, which suggests that serum hepcidin could be a potential biomarker for PCOS.
摘要：
■铁代谢在多囊卵巢综合征（PCOS）女性代谢紊乱的发展中起着重要作用。尽管铁调素很重要,一个关键的铁调节器，目前对PCOS患者血清hepcidin水平的研究显示出相互矛盾的结果.
■PubMed,Embase,WebofScience,从成立到2023年9月9日，系统搜索了Cochrane图书馆和中国国家知识基础设施（CNKI）数据库。该搜索旨在确定中英文研究，这些研究检查了PCOS女性与健康对照组相比的hepcidin水平。计算标准化平均差异（SMD）和相应的95％置信区间（95％CIs），以评估有和没有PCOS的女性之间血清铁调素水平的差异。
■荟萃分析共包括10项符合条件的研究，其中包括499名PCOS患者和391名对照受试者。汇总分析显示，与健康对照组相比，PCOS患者的血清铁调素水平显着降低（SMD=-3.49，95％CI：-4.68至-2.30，p<0.05）。体重指数(BMI)<25的PCOS患者和BMI≥25的PCOS患者血清铁调素水平差异无统计学意义(p>.05)。
■PCOS患者血清铁调素水平明显低于健康对照组,这表明血清铁调素可能是PCOS的潜在生物标志物。
■PubMed,Embase,WebofScience,从成立到2023年9月9日，系统搜索了Cochrane图书馆和中国国家知识基础设施（CNKI）数据库。该搜索旨在确定中英文研究，这些研究检查了PCOS女性与健康对照组相比的hepcidin水平。计算标准化平均差异（SMD）和相应的95％置信区间（95％CIs），以评估有和没有PCOS的女性之间血清铁调素水平的差异。
■荟萃分析共包括10项符合条件的研究，其中包括499名PCOS患者和391名对照受试者。汇总分析显示，与健康对照组相比，PCOS患者的血清铁调素水平显着降低（SMD=-3.49，95％CI：-4.68至-2.30，p<0.05）。体重指数(BMI)<25的PCOS患者和BMI≥25的PCOS患者血清铁调素水平差异无统计学意义(p>.05)。
■PCOS患者血清铁调素水平明显低于健康对照组,这表明血清铁调素可能是PCOS的潜在生物标志物。
